VaxInnate - Home

04/27/2010

VaxInnate's VAX125 Seasonal Flu Vaccine Shown Safe and Highly Immunogenic

We should be able to provide a much-needed

03/18/2010

Hofstaetter named President & CEO; Shaw named CSO & Chairman

We’re pleased that Thomas Hofstaetter has agreed to lead VaxInnate

01/12/2010

VaxInnate Licenses Recombinant H1N1 Pandemic Swine Flu Vaccine to Biological E.

Vaccine Could Become Available for Use in India This Year

All news

VaxInnate is developing novel, proprietary vaccines for pandemic and seasonal influenza.
Using our proven technology platform, VaxInnate has the potential to produce potent vaccines for a range of infectious diseases and help meet urgent public health needs.

	Vaccine Currently marketed influenza vaccines are based on a development, production and vaccination strategy that ... More



	Toll-Like Receptor (TLR) VaxInnate's TLR technology is based on the ability of "toll-like receptors" (TLRs) to recognize certain molecular patterns... More



	Background Biology The immune system takes two different, yet interdependent approaches to defeating a foreign pathogen... More



	All technologies

	VaxInnate Employees